Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + sunitinib
- Development stage
- Discontinued
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy regimen consists of bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), and sunitinib, a multi-targeted small molecule tyrosine kinase inhibitor. Investigated primarily by Memorial Sloan Kettering Cancer Center (MSKCC) for the treatment of metastatic renal cell carcinoma (mRCC), the rationale was to provide continuous antiangiogenic blockade by using bevacizumab to prevent rebound angiogenesis during the standard two-week rest period of sunitinib. However, clinical trials (Phase I/II) revealed significant overlapping toxicities, including severe hypertension, hematologic issues, and vascular complications, leading to the discontinuation of further development of this specific combination at the tested dose levels.
- Other names
- Bevacizumab and SunitinibSunitinib and Bevacizumab
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)VEGFA (Vascular endothelial growth factor A)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on bevacizumab + sunitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + sunitinib.